Drug Profile
Dectrekumab/VAK 694
Alternative Names: QAX-576/VAK-694; QBX-258; VAK-694/dectrekumab; VAK-694/QAX-576Latest Information Update: 24 Jun 2019
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 24 Jun 2019 Discontinued - Phase-II for Asthma in Germany, United Kingdom, USA (IV)
- 30 Jul 2015 Dectrekumab/VAK 694 is still in phase II trials for Asthma in the USA
- 01 Feb 2012 Phase-II clinical trials in Asthma in USA (IV)